Acquisition of a Leica Bond Rx Controller
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE ORDER AND NOT A REQUEST FOR QUOTATIONS.
This contract action is for the acquisition of supplies/equipment for which the Government intends to solicit and negotiate with only one source under the authority of Federal Acquisition Regulation (FAR) Subpart 13.106-1(b). The National Cancer Institute (NCI) intends to award a single source purchase order to Ferox LLC, Ellicott City, MD, for the acquisition of a Leica Bond Rx Controller.
The National Cancer Institute (NCI) needs to obtain a Bond Rx Controller for a clinical instrument (Leica Bond) Automated Immunohistochemistry stainer annual (1 year warranty included) and recommended Preventative Maintenance post-instrument relocation (with PM Kit included). The instrument will be used for validation of clinical IHC target markers for diagnostic and in some cases enrollment to NIH clinical trials. In the clinical research application, the Bond Rx instrument will be used for critical research in rare tumor identification and subsequent development of therapeutic mechanisms for patients undergoing treatments.
The anticipated period of performance will be for one year.
The applicable North American Industry Classification System (NAICS) code for this acquisition is 811210 – Electronic and Precision Equipment Repair and Maintenance and a size standard of $34M.
NCI will solicit and negotiate directly with Ferox LLC and no solicitation will be issued. Interested parties may identify their interest and capability. Award is subject to approval of the Sole Source Justification. This notice of intent is not a request for competitive proposals or quotations; however, an interested party may submit a statement of capabilities if they believe they can meet the above requirement. The statement of capabilities must be submitted in writing and contain sufficient detail to allow the Government to determine if the party can provide the requirement. A determination by the Government not to compete this proposed action based upon responses to this notice is solely with the discretion of the Government. All responses must be received within 7 days from the date of publication of this synopsis. Information received will normally be considered for the purpose of determining whether to conduct a competitive procurement. If no affirmative responses are received within 7 days of this notice, an award will be made to Ferox LLC. This procurement is to be processed using Simplified Acquisition Procedures. There is no solicitation package available. For any questions regarding this announcement, please contact Elizabeth Bulger via email Elizabeth.bulger@hhs.gov